Management of Drug Therapy for Leptomeningeal Metastasis of Sensitive Driver Gene Positive Non-small Cell Lung Cancer.
10.3779/j.issn.1009-3419.2020.102.18
- Author:
Zhiqin LU
1
;
Jing CAI
1
;
Zhimin ZENG
1
;
Anwen LIU
1
Author Information
1. Department of Oncology, The Second Affiliated of Nanchang University, Nanchang 330006, China.
- Publication Type:Journal Article
- Keywords:
Driver gene positive;
Drug therapy;
Leptomeningeal metastasis;
Lung neoplasms
- From:
Chinese Journal of Lung Cancer
2020;23(8):710-718
- CountryChina
- Language:Chinese
-
Abstract:
Leptomeningeal metastasis (LM) is one of the serious complications of advanced non-small cell lung cancer (NSCLC), although the incidence is not high, the clinical symptoms are severe and the prognosis is poor. LM is prone to occur in patients with positive driver gene than negative. At present, the treatment of LM mainly includes molecular targeted therapy, systemic chemotherapy, whole brain radiotherapy, intrathecal chemotherapy and immunotherapy. Although there are many treatments, the efficacy of LM is still unsatisfactory. This article reviews the drug therapy of sensitive driver gene positive NSCLC LM.
